BMS 817378Alternative Names: BMS-817378; SIM-817378
Latest Information Update: 02 Aug 2016
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 02 Aug 2016 Chemical structure information added
- 20 Jul 2016 Phase-I clinical trials in Cancer in China (unspecified route) (Simcere Pharmaceuticals pipeline, July 2016)